265 related articles for article (PubMed ID: 33601052)
1. Centyrin ligands for extrahepatic delivery of siRNA.
Klein D; Goldberg S; Theile CS; Dambra R; Haskell K; Kuhar E; Lin T; Parmar R; Manoharan M; Richter M; Wu M; Mendrola Zarazowski J; Jadhav V; Maier MA; Sepp-Lorenzino L; O'Neil K; Dudkin V
Mol Ther; 2021 Jun; 29(6):2053-2066. PubMed ID: 33601052
[TBL] [Abstract][Full Text] [Related]
2. Development of siRNA payloads to target KRAS-mutant cancer.
Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
[TBL] [Abstract][Full Text] [Related]
3. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
4. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.
Ganesh S; Koser ML; Cyr WA; Chopda GR; Tao J; Shui X; Ying B; Chen D; Pandya P; Chipumuro E; Siddiquee Z; Craig K; Lai C; Dudek H; Monga SP; Wang W; Brown BD; Abrams MT
Mol Cancer Ther; 2016 Sep; 15(9):2143-54. PubMed ID: 27390343
[TBL] [Abstract][Full Text] [Related]
5. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
6. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
7. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
8. Generation and validation of structurally defined antibody-siRNA conjugates.
Nanna AR; Kel'in AV; Theile C; Pierson JM; Voo ZX; Garg A; Nair JK; Maier MA; Fitzgerald K; Rader C
Nucleic Acids Res; 2020 Jun; 48(10):5281-5293. PubMed ID: 32347936
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.
Dudek H; Wong DH; Arvan R; Shah A; Wortham K; Ying B; Diwanji R; Zhou W; Holmes B; Yang H; Cyr WA; Zhou Y; Shah A; Farkiwala R; Lee M; Li Y; Rettig GR; Collingwood MA; Basu SK; Behlke MA; Brown BD
Mol Ther; 2014 Jan; 22(1):92-101. PubMed ID: 24089139
[TBL] [Abstract][Full Text] [Related]
10. EpCAM-targeted liposomal si-RNA delivery for treatment of epithelial cancer.
Bhavsar D; Subramanian K; Sethuraman S; Krishnan UM
Drug Deliv; 2016 May; 23(4):1101-14. PubMed ID: 25417832
[TBL] [Abstract][Full Text] [Related]
11. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
13. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.
Lee S; Ahn HJ
Acta Biomater; 2019 Jun; 91():258-269. PubMed ID: 31026519
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Centyrin-Based Near-Infrared Probe for Fluorescence-Guided Surgery of Epidermal Growth Factor Receptor Positive Tumors.
Mahalingam SM; Dudkin VY; Goldberg S; Klein D; Yi F; Singhal S; O'Neil KT; Low PS
Bioconjug Chem; 2017 Nov; 28(11):2865-2873. PubMed ID: 28945346
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi).
Xiang S; Keates AC; Fruehauf J; Yang Y; Guo H; Nguyen T; Li CJ
Methods Mol Biol; 2009; 487():147-60. PubMed ID: 19301646
[TBL] [Abstract][Full Text] [Related]
16. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi.
Guo H; Zhang J; Inal C; Nguyen T; Fruehauf JH; Keates AC; Li CJ
Gene Ther; 2011 Jan; 18(1):95-105. PubMed ID: 20811467
[TBL] [Abstract][Full Text] [Related]
18. A simplified and versatile system for the simultaneous expression of multiple siRNAs in mammalian cells using Gibson DNA Assembly.
Deng F; Chen X; Liao Z; Yan Z; Wang Z; Deng Y; Zhang Q; Zhang Z; Ye J; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Li M; Geng N; Zhao L; Zhou G; Zhang P; Luu HH; Haydon RC; Reid RR; Yang T; He TC
PLoS One; 2014; 9(11):e113064. PubMed ID: 25398142
[TBL] [Abstract][Full Text] [Related]
19. [Effect of β-catenin gene silencing by shRNA on biologic characteristics of human esophageal carcinoma cells].
Wang JS; Ji AF; Wen JF; Ren HZ
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):835-41. PubMed ID: 21215100
[TBL] [Abstract][Full Text] [Related]
20. Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells.
Zavoiura O; Brunner B; Casteels P; Zimmermann L; Ozog M; Boutton C; Helms MW; Wagenaar T; Adam V; Peterka J; Metz-Weidmann C; Deschaght P; Scheidler S; Jahn-Hofmann K
Mol Pharm; 2021 Mar; 18(3):1048-1060. PubMed ID: 33444501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
